The objective of the present study is to investigate the effect of PPARγ and RBP4 polymorphisms on body mass, insulin resistance and dyslipidemia among HIV-infected patients with anti-retroviral therapy after adjusting other risk factors, including influence of anti-retroviral regimen, diet and drinking. This evidence concerns the gene RBP4 and metabolic syndrome.